Abstract:BackgroundConsensus is lacking on what constitutes a meaningful score change for individual patients on clinical outcome assessments (COAs) that are commonly used in clinical trials of Alzheimer’s disease. Such thresholds are one important approach to help contextualize trial results and demonstrate meaningful treatment benefit.ObjectivesTo estimate meaningful within-patient change thresholds for the Clinical Dementia Rating Scale — Sum of Boxes (CDR-SB), Alzheimer’s Disease Assessment Scale — Cognitive Subscale (ADAS-Cog), and the Mini-Mental State Examination (MMSE) among participants with mild cognitive impairment (MCI).DesignRetrospective anchor- and distribution-based analyses of data from the ADC-008 (NCT00000173) study were used to estimate thresholds for meaningful within-patient change on the target measures.SettingAnalyses were conducted using data from ADC-008 a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study among participants with the amnestic subtype of MCI, which was conducted by the Alzheimer’s Disease Cooperative Study (ADCS) between March 1999 and January 2004 in the United States and Canada.ParticipantsAnalyses were based on 769 eligible participants who completed the baseline assessment from 69 ADCS sites in the United States and Canada.MeasurementsThe target outcome measures for this analysis included the CDR-SB, the ADAS-Cog, and the MMSE. The anchor measures for this analysis included the Global Deterioration Scale and the MCI—Clinical Global Impression of Change.ResultsFocusing on the 12-month time point, within-patient increases of 1–2.5 points in the CDR-SB and increases of 2–5 points on the 11-item ADAS-Cog and 13-item ADAS-Cog, on average, reflect minimal-to-moderate levels of deterioration, respectively.ConclusionsThese thresholds may be useful to aid the interpretation of Alzheimer’s disease clinical trial data by illustrating meaningful within-patient progression over the course of a clinical trial via supplementary progressor analyses, which may in turn be informative for treatment decisions. Estimates generated via these methods are specifically intended to evaluate within-patient change and are not intended to assess the magnitude and meaningfulness of differences between group-level changes over time.

Conceptualizing meaningful between-group difference in change over time: a demonstration of possible viewpoints

Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease

When Average Isn't Good Enough: Identifying Meaningful Subgroups in Clinical Data

Comparison of anchor-based methods for estimating thresholds of meaningful within-patient change using simulated PROMIS PF 20a data under various joint distribution characteristic conditions

An Introduction to Clinical Significance: An Alternative Index of Intervention Effect for Group Experimental Designs

The Importance of the Principle of Clinical Significance—Defining Significant to Whom and for What Purpose: A Response to Tingey, Lambert, Burlingame, and Hansen

Care partner‐informed meaningful change thresholds for the Clinical Dementia Rating‐Sum of Boxes for trials of early Alzheimer's disease

Expectations and clinical meaningfulness of randomized controlled trials

How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales

Bayesian Solutions for Assessing Differential Effects in Biomarker Positive and Negative Subgroups

Change analysis for intermediate disease markers in nutritional epidemiology: a causal inference perspective

Analyzing Two-Phase Single-Case Data with Non-overlap and Mean Difference Indices: Illustration, Software Tools, and Alternatives

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force

Why (not) rely on patients' perspectives? Time for a meaningful standard to measure and define patient-specific change in clinical psychology.

Clinical importance in Alzheimer's disease: effects of anchor agreement and disease severity

Abstract 12112: Establishing a Minimally Clinically Important Difference Threshold for Health-Related Quality of Life in Atrial Fibrillation: The SAGE-AF Study

Detecting critical treatment effect bias in small subgroups

Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.

Testing the applicability of idionomic statistics in longitudinal studies: The example of 'doing what matters'

The Minimal Clinically Important Difference: A Review of Clinical Significance

Clinician's Approach to Advanced Statistical Methods: Win Ratios, Restricted Mean Survival Time, Responder Analyses, and Standardized Mean Differences